Navigation Links
The Astellas European Foundation Winner of Transplantation Grant 2011 Announced
Date:9/6/2011

GLASGOW, Scotland, September 7, 2011 /PRNewswire/ --

The Astellas European Foundation is delighted to announce the winner of the 2011 Transplantation Grant:

Dr Christian Toso of the University of Geneva, Switzerland

Last evening, the University's team, led by Dr Toso, received the grant of US$ 300,000 to support work on their project entitled 'Towards a tailored immuno-suppression after liver transplantation for hepatocellular carcinoma' at the Astellas European Foundation Award presentation.

Dr Ayad Abdulahad, Astellas European Foundation Trustee and Vice President Medical Affairs and Health Economics for Astellas Pharma Europe Ltd. commented, "We received many entries of a very high standard which covered a broad range of topics across Europe.  In the face of very strong competition the Jury chose Dr Toso's research based on its potential impact on clinical practice.  The team's aim is to tailor immunosuppressive strategy for individual patients with hepatocellular carcinoma. It is very exciting and, in the future, their results could possibly be applied to other cancers."

At the Award Presentation Event in Glasgow, UK, the Astellas European Foundation emphasised their continued and long term commitment to research and development in the field of transplant medicine.

Dr Toso said, "We thank the Astellas European Foundation for its generous support. Although liver transplantation is the most efficient treatment for patients with early  unresectable hepatocellular carcinoma, some 10% of recipients still experience recurrence after transplantation. The aim of our study is to define the ideal immunosuppression strategy, both clearing cancer cells and preventing rejection. Such a study has the potential to better tailor immunosuppression after liver transplantation for cancer, improve outcomes and qualify some currently excluded patients with more advanced HCCs for transplantation."

The Astellas European Foundation is a registered charity. It was established in 2005 with the  goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. The Astellas European Foundation Transplantation Grant supports basic medical and related scientific programmes which contribute to advancements in transplant medicine.  The winner of the grant was chosen by a Jury that includes independent European transplantation leaders.

http://www.astellas.com/eu


Notes to Editors

About The Astellas European Foundation

The Astellas European Foundation is a registered charity, established in 2005, with the long-term goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. The Astellas European Foundation is registered with the Charity Commission for England and Wales with number 1036344.

About Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organisation is committed to becoming a global company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East, and Africa, an R&D site, and three manufacturing plants. The company employs approximately 4,000 staff across these regions.



'/>"/>
SOURCE Astellas European Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
2. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
3. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
4. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
5. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
6. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
7. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
8. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
9. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
10. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
11. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life sciences, ... team to bring a wealth of insight to a growing business. ... knowledge. George Phillips joined ArisGlobal in the ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... Memorial Healthcare System Graduate Medical ... (ACGME) that it has received accreditation for its residency program on Physical Medicine ... that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation allows ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members ... celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural Health Care ... Cumming), offers a 70% tax credit to individuals and corporations which donate directly to ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White ... repaying their loans, more information about their loan terms and accounts, and more ... loan debt, including federal and private loans, has reached $1.3 trillion, with 43 ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
Breaking Medicine News(10 mins):